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To discover potential prognostic biomarkers of Lacunar infarction
(LACI), here we present quantitative proteomics data of plasma
microvesicle-enriched fraction derived by comparative isobaric proﬁl-
ing of three groups of prospectively followed-up LACI patients (LACI –
no adverse outcome, LACI –recurrent vascular event and LACI –
cognitive decline) and a demographically matched control group. We
conﬁdently (unused prot score43, FDR¼1.1%) identiﬁed 183 proteins,
43 out of which were signiﬁcantly regulated (p-valueo0.05) in at least
one of the three LACI groups in comparison to control group.
Bioinformatics analysis and data mining revealed upregulation of
brain-speciﬁc proteins including myelin basic protein, proteins of
coagulation cascade (e.g., ﬁbrinogen alpha chain, ﬁbrinogen beta
chain) and focal adhesion (e.g., integrin alpha-IIb, talin-1, and ﬁlamin-
A) while albumin was downregulated in both groups of patients with
adverse outcome. The data of this study are also in line with our
previously published article entitled “Discovery of prognostic biomar-
ker candidates of Lacunar infarction by quantitative proteomics of
microvesicles enriched plasma” by Datta et al. (2014). The raw data
had been deposited to the ProteomeXchange consortium with
identiﬁer PXD000748.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ier Inc. This is an open access article under the CC BY license
: þ65 67913856.
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A. Datta, S.K. Sze / Data in Brief 4 (2015) 510–517 511Speciﬁcations tableSubject area Biotechnology, medicine-More speciﬁc
subject areaQuantitative proteomics, Lacunar infarction, Prognostic biomarkerType of data Table, ﬁgure and excel ﬁle
How data was
acquiredQStar Elite mass spectrometer(Applied Biosystems/MDSSciex, Foster City, CA, USA) coupled with online
microﬂow HPLC systemData format Raw:.wiff ﬁles generated with Analyst QS2.0 software (Applied Biosystems).Analyzed: Proteinpilot
Group ﬁles processed by ProteinPilot™ software3.0 (revision number 114732; Applied Biosystems)Experimental factors Micro-vesicles were isolated from plasma specimens by sequential normal and ultra-centrifugation. They
were lyophilized and dissolved in sodium dodecyl sulfate containing dissolution buffer prior to in-gel
digestion, isoberic labeling, chromatographic fractionation and mass spectrometry.Experimental
features Multi-dimensional liquid chromatography coupled with mass spectrometry
✓ 4-plex Isobaric tags for relative and absolute quantiﬁcation (iTRAQ)( Applied Biosystems)
✓ Electrostatic repulsion and hydrophilic interaction chromatography (ERLIC)Data source location Singapore
Data accessibility All data are available with this article. The proteomics raw data ﬁles can be found at ProteomeXchange
with identiﬁer PXD000748.Value of the data Our study is the ﬁrst of its kind where an iTRAQ-guided discovery proteomics approach was used to identify potential
prognostic circulatory biomarkers of ischemic stroke.
 Bioinformatics analysis and data mining revealed upregulation of brain-speciﬁc proteins including myelin basic protein,
proteins of coagulation cascade (e.g., ﬁbrinogen alpha chain, ﬁbrinogen beta chain) and focal adhesion (e.g., integrin alpha-
IIb, talin-1, and ﬁlamin-A) while albumin was downregulated in both groups of LACI patients with adverse outcome.
 The short-listed candidate prognostic biomarkers from this data set may stimulate validation studies on independent
cohort of individual LACI patients.
 In absence of clinically proven circulatory biomarkers, these candidates can also be tried as surrogate markers in LACI-
related clinical trials to check the consequences of therapeutic interventions.
 From an academic standpoint, this data set may offer important insight into the mechanisms of poor prognosis
following LACI.1. Experimental design, materials and methods
Biomarker for prognosis of ischemic stroke is a relatively new concept compared to biomarkers for
diagnosis. No single or panel of blood-based biomarkers has been validated by clinical trials for stroke or
related secondary complications. The short-term prognosis of ischemic cerebral small-vessel disease
(SVD), including Lacunar infarction (LACI) is more favorable, with almost negligible early mortality,
absence of neuropsychological impairment and an excellent neurological recovery. However, LACI causes
an increase in the mid- or long-term risk of recurrent vascular disorder and of different types of vascular
dementia or neuropsychological abnormalities [2]. On the other hand, routinely used brain imaging
techniques are often not sufﬁcient to produce high resolution images for patients with LACI affecting small
arterioles (0.2–0.8 mm) and having smaller size than the larger territorial infarct seen in non-lacunar
strokes [3]. Hence, prognostic biomarkers for LACI will complement the existing symptomatic and
diagnostic protocols used for patient management.
Plasma microvesicle is a good source of disease biomarkers that entered the circulatory system
following their release by cells from various tissues including the cells of central nervous system [4–7].
Ischemic SVD is well-known to cause an endothelial dysfunction and a diffuse increase in the blood
brain barrier (BBB) permeability that may facilitate the leakage of microvesicles in the general
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inﬂuence of ischemic stress may release microvesicles into circulation through the compromised BBB
during its evolution. Accordingly, we targeted plasma microvesicle enriched fractions for proﬁling
through iTRAQ‐2D‐LC‐MS/MS strategy [9–12]. An ofﬂine weak anion exchange (WAX) chromatography
(PolyLC, Columbia, MD, USA) was followed by an online reverse phase chromatography and tandem
mass spectrometry with QSTAR Elite Hybrid MS (Applied Biosystems/MDS-SCIEX, Foster City, CA, USA).
The mass spectrometric data analysis was performed using Analyst QS 2.0 (Applied Biosystems) and
ProteinPilot Software (v 3.0, Revision Number: 114 732, Applied Biosystems) software while the
bioinformatics analysis was performed with DAVID and GenePattern (version 3.3.3) software.2. Collection of samples and clinical information
All patients with recent transient ischemic attacks (TIA) or nondisabling ischemic stroke who were
seen at the Singapore General Hospital between 1999 and 2005 were screened for eligibility for the
European Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT). The ESPRIT trial was
registered under http://clinicaltrials.gov with the identiﬁer NCT00161070. Patients recruited into ESPRIT
were eligible to enter a cognitive substudy (ESPRIT-Cog). Detailed methodology of ESPRIT and ESPRIT-
cog including the exclusion criteria have been reported previously [1,13,14]. Stroke subtype was
classiﬁed according to the Oxfordshire Community Stroke Project as total anterior circulation infarct,
partial anterior circulation infarct, posterior circulation infarct, or LACI [15]. The patients were eligible if
they were within six-months of a TIA (including transient monocular blindness) or nondisabling
ischemic stroke [grade r3 on the modiﬁed Rankin scale (mRS)] of presumed arterial origin [16].The
control plasma was collected from non-stroke subjects at the same site during 2004–2006.
Risk factor information (e.g. diabetes mellitus status, hypertension, hyperlipidemia, smoking status)
was collected at baseline. The cognitive status of the patients was determined by trained research
psychologists using standard neuropsychological test battery that has been validated for use in
Singapore. Details of the procedure have been described previously [1,14,17]. Diagnoses of dementia
were made according to the DSM-IV criteria [18]. Diagnoses of various stages of dementia were made
after each patient's baseline and follow up visits.3. Experimental design guided by outcome measures
Of the 458 patients enrolled in the Singapore General Hospital's site of the ESPRIT trial, 26 (6%)
refused to provide blood samples and were excluded from the study. Hence, 432 consented to
participate in the ESPRIT-Cog substudy. Of these 432 patients, 275 (64%) had LACI, which was the
population of interest for the current study. Further, 10 were excluded as they had dementia at baseline.
Several patients had insufﬁcient plasma samples or dropped out during the follow up period and were
therefore excluded. Representative 45 (45/265, 17%) LACI patients were selected for this discovery
proteomics study. Notably, there were no differences in demographic characteristics between these 45
and remaining 220 LACI patients of this cohort (data not shown).
The LACI patients were followed up annually for up to 5 years (median follow up 3 years; interquartile
range, 2 years) to monitor for the occurrence of any vascular event or for change in the cognitive status.
Strokes, peripheral artery disease, intracranial bleeds, and any cardiac ischemia (stable and unstable
angina, myocardial infarctions) or deaths from any of the abovewere considered to be a recurrent vascular
event. Any LACI patient having a recurrence of vascular event during the follow-up period was included in
the group called “recurrent vascular event” [14,19]. The patients whose cognitive status declined from the
respective baseline status during the course of the prospective study had been assigned to the “cognitive
decline” group. Patients who did not suffer a recurrent vascular event or cognitive decline during this
period were grouped as “LACI, no adverse outcome”. Accordingly, plasma samples of 45 LACI patients
were divided into three groups based on the outcome variables (LACI – no adverse outcome, n¼19; LACI –
recurrent vascular events, n¼11; LACI – cognitive decline but no recurrent vascular events, n¼15). The
Fig. 1. Schematic representation of the experimental design along with key ﬁndings and supporting data.
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normal at the baseline. The experimental design is depicted in Fig. 1.
The demographic characteristics, baseline risk factors and cognitive classiﬁcations of the study
population stratiﬁed by outcome measures and control group are summarized in Table S1. The
average age of the recruited subjects was 61710 years; 55% were males and 92% were Chinese. No
signiﬁcant difference was observed between three groups of LACI patients in terms of most of the
baseline risk factors except ‘smoking’ (H(2)¼7.276, p¼0.026).
The plasma samples were pooled group-wise before processing. A microvesicle-enriched fraction was
isolated by sequential centrifugation combined with ultracentrifugation and labeled with isobaric tags
that was followed by 2D LC-MS/MS analysis to improve the depth of identiﬁcation and quantiﬁcation. The
iTRAQ samples were injected thrice in the LC-MS/MS analysis (technical replicate¼3).4. Pre-proteomics sample preparation
4.1. Separation of microvesicle-enriched fraction by sequential centrifugation
Frozen individual plasma samples were thawed on ice and pooled in a group-wise manner to
obtain four tubes containing around 5 ml of plasma specimens from each group. The samples were
A. Datta, S.K. Sze / Data in Brief 4 (2015) 510–517514subjected to sequential centrifugation to enrich the microvesicles using a modiﬁed protocol as
described previously [20,21]. Brieﬂy, sonicated plasma (5X 1 min) was centrifuged at 4000g twice for
30 min and then at 12,000g for 30 min to collect and remove the pellets. The resulting supernatant
was subsequently diluted approx. ﬁve times with ice-cold 1X PBS before doing ultra-centrifugation at
30,000g for 2 h to collect the pellet of plasma membrane derived vesicles or microparticles for a
separate study. The supernatant was ultra-centrifuged again at 200,000g for 2 h 15 min to collect the
microvesicle pellet (Fig. 1). The microvesicle pellets were washed at least twice with 1X PBS and were
lyophilized. The lyophilisate was dissolved using 50–100 ml of ice-cold dissolution buffer [6% sodium
dodecyl sulfate; 20 mM dithiothreitol, 100 mM Tris–HCl with Complete Protease Inhibitor Cocktail
(COMPLETE, (Roche; Mannheim, Germany)), pH 7.75] by brief vortexing. Protein quantization was
performed using 2-D Quant kit (Amersham Biosciences, Piscataway, NJ, USA).5. Proteomics
5.1. In-gel tryptic digestion and isobaric labeling
The samples (500μg/condition) were subjected to denaturing PAGE using a 4–6–25% gel following
an identical procedure as described previously [10,11]. Brieﬂy, the diced gel bands were extensively
washed with 25 mM triethylammonium bicarbonate (TEAB) in 50% acetonitrile (ACN) to completely
remove Tris HCl and detergent before reduction (in 5 mM tris (2-carboxyethyl) phosphine, 25 mM
TEAB, 60 1C, 1 h) and alkylation (in 10 mM methyl methanethiosulfonate in 25 mM TEAB in dark, RT,
45 min). They were digested overnight (12.5 ng/μl of sequencing-grade modiﬁed trypsin) ((Promega,
Madison, WI, USA), in 50 mM TEAB, 2% ACN) at 37 1C. Subsequently, the peptides were extracted and
dried before reconstituting them into 0.5 M TEAB and labeled with respective isobaric tags of 4-plex
iTRAQ Reagent Multi-Plex kit (Applied Biosystems) for 2 h as follows: Control, 114; LACI – no adverse
outcome, 115; LACI – recurrent vascular events, 116; LACI – cognitive decline but no recurrent vascular
events, 117 (Fig. 1). The labeling reaction was stopped by addition of water in each tube before
combining all four groups for vacuum centrifugation.6. Electrostatic repulsion and hydrophilic interaction chromatography (ERLIC)
The dried iTRAQ-labeled peptides were desalted by Sep-Pak C18 SPE cartridges (Waters, Milford,
MA, USA). A modiﬁed ERLIC with volatile salt-containing buffers was adopted using a hydrophilic
WAX column (PolyWAX LP, 2004.6 mm2; 5 mm; 300 Å) (PolyLC) that was conditioned overnight by
periodic and intermittent washing with the chromatographic buffers and 0.5 M KCl [11,22]. The
iTRAQ-labeled peptides were reconstituted in 200 ml of Buffer A (10 mM NH4HCO2, 85% ACN, 0.1%
formic acid (FA)) and fractionated on a Prominence HPLC system (Shimadzu, Kyoto, Japan) in a 65 min
gradient with Buffer B (30% ACN, 0.1% FA). The HPLC gradient was composed of 100% buffer A for
10 min; 0–25% buffer B for 35 min; then 25–100% buffer B for 10 min; followed by 100% buffer B for
10 min. The chromatogram was recorded at 280 nm. Eluted fractions were collected in every 1 min,
and then pooled into 34 fractions depending on the peak intensities, before drying them in a vacuum
centrifuge. They were stored at 20 1C till MS analysis.7. Reverse phase LC-MS/MS analysis using QSTAR
The iTRAQ-labeled peptides were reconstituted with 0.1% FA, 3% ACN and analyzed using a HPLC
system (Shimadzu) coupled with QSTAR Elite Hybrid MS (Applied Biosystems/MDS-SCIEX) as
described previously with minor modiﬁcations. Brieﬂy, most of the LC parameters for a 90 min
gradient including column conﬁguration, gradient and ﬂow rate were kept constant except the mobile
phase A composition (0.1% FA in 3% ACN) and sample injection volume (15 ml/injection). Regarding MS
parameters, the precursors with a mass range of 300–1600m/z and calculated charge of þ2 to þ5
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with a 50 mDa mass tolerance. The maximum accumulation time was set at 1.0 s. All other MS
parameters were kept identical as reported previously [10].8. Mass spectrometric raw data analysis
The Analyst QS 2.0 software (Applied Biosystems) was used for the spectral data acquisition. Spectra
acquired from each of the technical replicates were submitted alone and together to ProteinPilot
Software (Applied Biosystems) for peak list generation, protein identiﬁcation and quantiﬁcation against
the concatenated target-decoy Uniport human database (191242 sequences, downloaded on 12 March
2012 from www.uniprot.org). The false discovery rate (FDR) of peptide identiﬁcation was set to be less
than 1% (FDR¼2.0decoy_hits/total_hits). Details of the analysis strategy have been described
previously [10]. The proteins and peptides that are identiﬁed and quantiﬁed by iTRAQ experiment were
exported from ProteinPilot and listed in the Table S2 (Protein summary) and Table S3 (Peptide
summary). Hundred eighty three proteins were identiﬁed when a strict cut-off of unused prot score 43
(corresponds to 99.9% conﬁdence) was adopted to keep the FDR at 1.1%. However, 288, 377 and 458
proteins were identiﬁed with unused score Z2 (499% conﬁdence), 41.3 (495% conﬁdence) and
41.0 (490% conﬁdence) respectively. Filtering the protein list with a p-value cut-off of o0.05 resulted
in a shortlist containing 17, 33 and 28 proteins for the three ratios (i.e. 115/114, 116/114 and 117/114)
respectively after excluding the keratins from the list. Overall, 43 proteins having at least one ratio with
an acceptable level of conﬁdence were shortlisted for the bioinformatics analysis to retrieve useful
biological trends (Table S4).9. Bioinformatics analysis
The open-source software DAVID (http://david.abcc.ncifcrf.gov/) and GenePattern (www.broad
institute.org/cancer/software/genepattern/) were used for the enrichment and clustering analysis by
submitting Uniprot accession numbers of the short-listed 43 proteins [23,24]. Different attributes of
DAVID such as gene ontology (GO), pathway, protein interaction, keywords and tissue speciﬁcity were
used to extract out hidden trends and enrichment of certain groups of proteins. DAVID uses modular
enrichment analysis where the term–term/gene–gene relationships are considered for enrichment
p-value calculation. It calculates the probability of the number of genes in the list that hit a given biology
class as compared to pure random chance with the aid of Fisher's exact test. To check the enrichment,
p-valuer0.01 and FDR o1% were used as a cut-off. Searching for enriched pathways using various
modules (e.g. KEGG, Biocarta, Reactome) showed ‘complement and coagulation cascades’, ‘intrinsic
prothrombin activation pathway’ or ‘integrin cell surface interactions’ (e.g. ITGA2B, TLN1, FGB and FGA)
as signiﬁcantly over-represented (Fig. 1A, Table S4) with a differential trend among the groups of ‘no
adverse’ and ‘adverse’ outcome.
Hierarchical clustering algorithm of GenePattern uses Pearson correlation analysis between Log2-
transformed ratios of each protein with various conditions to generate a tree structure, which is
referred to as dendrogram. The clustering analysis result classiﬁed the proteins into two major clusters
(Figure S1I and II) separating the up- and downregulated proteins in adverse outcome groups.10. Western Blot (WB) Analyses
ALB was one of the most deregulated candidates as per the iTRAQ data in the groups with adverse
outcome (Table S4, Figure S1). WB was performed after SDS-PAGE by probing with anti-ALB primary
antibody (albumin, 1:5000, rabbit polyclonal; Abcam, Cambridge, UK) to check the technical reliability
of the iTRAQ result. 20 mg proteins were used for WB. Immunoreactivity was detected using an HRP
chemiluminescent substrate reagent kit (Invitrogen, Carlsbad, CA, USA). The WB result showed
consistent trends with the iTRAQ result (Fig. 1B).
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All statistical analyses were performed using SPSS 13.0 for Windows software (SPSS Inc.). One-way
ANOVA followed by post-hoc Tukey test was used for scale variables such as age. Nonparametric
Kruskal–Wallis H Test was used for comparing ordinal variables such as demographic characteristics
and baseline risk factors. Statistical signiﬁcance was accepted at po0.05.12. Limitations
Our study has few limitations. First, the LACI patients were recruited over a longer span (6 years. vs
2 years.) compared to the control subjects, making the average storage duration longer for LACI
patients than the control subjects. Second, the samples had been stored for at least 5 years (up to
maximum 12 years) at 80 1C, which should be taken into account before comparing the data with
similar studies during a meta-analysis. Notably, major part of the waiting time is included in the study
duration as long-term outcome variables were targeted to discover potential prognostic biomarkers.
Further, similar storage time is a common occurrence in biomarker studies and shown to adequately
preserve the quality of frozen samples when compared with freshly collected specimens for various
circulatory proteins such as insulin-like growth factor-I and transforming growth factor β [25,26].Conﬂict of interest
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